Hi [[ session.user.profile.firstName ]]
Sort by:
    • Resource Management & Planning for Successful Clinical Trials Resource Management & Planning for Successful Clinical Trials Rick Morris, President of R2 Consulting & Edward Davis, Director of Advisory & Solutions at Kforce Inc. Recorded: Nov 11 2015 6:00 pm UTC 47 mins
    • Clinical Trial planning and resource management can be one of the most complex management challenges facing life sciences organizations and CROs. Often these organizations are managing hundreds of studies across thousands of sites and investigators making it extremely difficult to understand how and where to deploy costly clinical resources. With the variability of the studies and the massive competition in the industry, finding a solution to understand how and where all clinical resources are being utilized and a solution with the ability to perform predictive analysis on this information to improve site and investigator selection can give companies a competitive edge.

      CA PPM for Clinical Research Planning from R2 Consulting gives you all of the tools needed to perform predictive analysis, plan and manage resource utilization, lower costs on expenses, and gather valuable information to assist in recruitment planning for sites and investigators.

      Join us for a webinar on Tuesday, 11/11 to learn how several life sciences and Clinical Research Organizations (CROs) have been able to leverage CA PPM for Clinical Research Planning to lower the complexity associated with clinical trial design resulting in reduced costs and more effective clinical trial management.

      Read more >
    • Patient engagement: the future for outcomes research and clinical trials? Patient engagement: the future for outcomes research and clinical trials? Dominic Tyer Recorded: Jun 25 2015 2:00 pm UTC 60 mins
    • There is growing momentum and recognition among researchers, regulatory agencies, policy makers and payers towards a more patient-centric approach to health outcomes research, including development and validation of Clinical Outcome Assessments, and participation of patients in clinical trials.

      On 25th June 2015 at 3pm (GMT) PMGroup, in association with Adelphi Values, will host a free webinar that shows how a more patient-centered approach can be used to enhance outcomes research and conduct of clinical trials, providing examples from research in oncology and inflammatory disease.

      The webinar will also demonstrate the importance of patient engagement at all stages of PRO development and will include direct feedback from a patient advisor, so you can learn about their experience as a partner in the research process.

      Read more >
    • Pitfalls in Post-Grant Trials Pitfalls in Post-Grant Trials Eugene Perez & Gerald Murphy, partner, Birch Stewart Kolasch Birch LLP; Michael Loney, Americas editor, Managing IP Recorded: May 12 2015 8:00 pm UTC 66 mins
    • Managing IP’s next webinar, run in cooperation with Birch Stewart Kolasch Birch LLP, will take place on May 12 at 4pm (eastern standard time); 1pm (pacific standard time) and will discuss ‘Pitfalls in Post-Grant Trials’.

      The popularity of USPTO post-grant patent trials have only increased. Whether the PTAB institutes an inter partes review, a post-grant review, or a post-grant validity review of qualified business method patents, each trial has procedural pitfalls with considerable strategic considerations during the Second Phase of the trial (from the institution decision to the final written decision by the Board). This webinar will explore the most common mistakes the third party petitioner or patent owner during the 2nd Phase, with an explanation of key decisions by the PTAB (including those posted on the USPTO microsite) as well as the Federal Circuit. The focus will be on discovery, the patent owner motion to amend, oral hearing, and estoppel.

      Speakers include:
      •Michael Loney, Americas editor, Managing IP (moderator)
      •Eugene Perez, partner, Birch Stewart Kolasch Birch LLP
      •Gerald Murphy, partner, Birch Stewart Kolasch Birch LLP

      With post-grant trials becoming increasingly popular, having an in-depths understanding of the pitfalls and challenges is essential for sustaining a strong presence in the market place. The live audience will be able to ask questions of the speakers during the webinar, which will be in English and will last one hour.

      This webinar relates to our April 16 discussion focusing on ‘Pitfalls in the first phase of Post Grant Proceedings’. You can listen to it here: https://www.brighttalk.com/webcast/327/149005

      Read more >
    • The JDSU Verdict: Lessons from a Securities Class Action Trial The JDSU Verdict: Lessons from a Securities Class Action Trial Jordan Eth, Allan Kleidon, Bruce Carton Recorded: Mar 25 2009 6:00 pm UTC 63 mins
    • On March 25, 2009, Cornerstone Research is sponsoring a webcast entitled "The JDSU Verdict One Year Later: Lessons from the Largest Securities Class Action Trial in History" that will feature two of the key players in that historic trial.

      Jordan Eth, co-lead trial counsel for JDS Uniphase and several individual defendants, and Allan Kleidon, testifying expert for the defense on damages and causation issues, will lead a discussion of the extraordinary lessons learned from the rarest of events: a jury trial in a securities class action lawsuit. The panel will discuss their experience in defending this massive securities class action at trial, including the unique challenges, trial tactics and considerations posed by a trial in this type of case. In addition, the panel will discuss the effective use of expert witnesses in a securities class action trial.

      Please join Jordan Eth, a partner at Morrison & Foerster LLP, and Allan Kleidon, Senior Vice President with Cornerstone Research, as they address these topics as well as your questions in a free, one-hour webcast. Moderated by Securities Docket's Bruce Carton.

      Read more >
    • Supporting emerging R&D companies to deliver research in the NHS Supporting emerging R&D companies to deliver research in the NHS Matt Cooper, Business Development and Marketing Director, NIHR Clinical Research Network Recorded: Oct 20 2015 10:00 am UTC 38 mins
    • •Is your company seeking to enter the clinical trial process?
      •Do you need expert advice on setting up a study?
      •Would you like help developing your protocol for the NHS environment?

      Supporting high-quality commercial contract clinical research across all therapeutic areas is a high priority for the National Institute for Health Research Clinical Research Network – the research delivery arm of the NHS.

      We support the full spectrum of commercial clinical research including medical technology, device and diagnostic studies in addition to pharmaceutical products. We have dedicated research support staff and services to assist with study delivery at site level. This infrastructure provides you with unparalleled access to, and understanding of, the NHS research environment.

      As well as helping you to navigate the NHS, we offer a range of practical services that can be tailored to your needs and are designed to help you set-up and deliver commercial research studies to time and target, whatever their size, design or therapeutic area. These include:

      •Feasibility; early feedback during protocol development, site intelligence and site identification
      •Commercial costing templates to expedite cost negotiations
      •Streamlined processes for gaining NHS permissions
      •Model agreements for faster contracting
      •Study management and delivery by our dedicated GCP-trained research workforce

      If you would you like to know more about our services you can join our live webinar hosted by Matt Cooper, Business Development and Marketing Director. This live online event will include a 30 minute presentation followed by an opportunity to ask questions.

      Read more >
    • Social Media Trials and Tribulations in Pharma Social Media Trials and Tribulations in Pharma John Mack, Pharma Marketing News Recorded: Feb 9 2012 2:00 pm UTC 41 mins
    • "Pharma's Social Media Trials and Tribulations"

      A Record of Social Media Events Impacting the Pharmaceutical Industry

      The pharmaceutical industry is at a turning point in its adoption of new social media tools and applications for communication with healthcare professionals, consumers, patients, policymakers, and payers. Practically every pharmaceutical company has launched a social media project or application of one sort or another. To be sure, not all these efforts have been successful. This presentation will explore what worked and what didn't by highlighting the major trials and tribulations of pharma's social media "road trip"

      Topics and discussion points include:

      Is the Industry Ready for Social Media? Results of the Pharmaguy Social Media Readiness Self-Assessment Survey
      History of FDA's Promise to Provide Social Media Guidelines. What's Gumming Up the Works?
      The Major Milestones of Pharma Use of Social Media: The Good, the Bad, and the Ugly. All Offer Useful Lessons.

      Read more >
    • Insider Trading Enforcement Update Insider Trading Enforcement Update Lawrence Gerschwer, Allen D. Applbaum Recorded: Mar 11 2014 5:00 pm UTC 62 mins
    • This webcast will highlight important recent developments in the government’s ongoing crackdown on insider trading, including lessons learned from recent high-profile criminal trials and debated legal issues. The panel will address:

      • The recent separate trials of former SAC Capital portfolio managers Mathew Martoma and Michael Steinberg in the Southern District of New York.
      • The effect prosecutions involving information from expert networks may have on the “mosaic theory.” Mosaic theory is the concept under which the SEC theoretically permits investors to piece together immaterial nonpublic information to form an investment thesis.
      • The sentences—usually no jail time—handed down to defendants who plead guilty and cooperate with the government’s investigation, versus the relatively long sentences of defendants who are convicted at trial.

      The speakers will include Lawrence Gerschwer, Partner, Morrison & Foerster LLP, and Allen D. Applbaum, Senior Managing Director and Global Leader of FTI Consulting’s Global Risk & Investigations Practice. Mssrs. Gerschwer and Applbaum are both former Assistant US Attorneys for the Southern District of New York.

      Read more >
    • Accelerating the Timeline to First-in-human Trials Accelerating the Timeline to First-in-human Trials David Edwards, Capsugel; Tim Scott, Pharmatek Laboratories; Joseph Forth, AMRI Recorded: Jul 13 2010 3:00 pm UTC 85 mins
    • Accelerating the Timeline to First-in-human Trials: NEW Case Studies on API in Capsule Technology

      Accurately and precisely dispensing drug substances alone, in tiny amounts as low as 100 micrograms into capsules, excipients or bulking agents is changed the process of drug development.

      Today, Pharma companies use micro-dosing technology to shorten drug development by reducing the need for costly time-consuming stability and pre-formulation studies. Reducing the time it takes to reach the critical "first in human" clinical decision point allows an increase in throughput of candidate compounds for development, thereby enabling pharma development departments to focus their resources on potential winners.

      This webinar will feature NEW case studies on the Capsugel technology. Speakers include:

      David Edwards, Director of Pharmaceutical Technology, Capsugel
      Tim Scott, President, Pharmatek Laboratories
      Joseph Forth, Manager, Pharmaceutical Development AMRI

      Read more >
    • Effective obviousness arguments in district court and PTAB Effective obviousness arguments in district court and PTAB Robert A. Surrette, President, McAndrews, Held & Malloy; Mary Elizabeth Mauro, Intellectual Property Counsel, Stryker Corp Recorded: Nov 4 2015 5:00 pm UTC 61 mins
    • Managing IP’s upcoming webinar ‘Effective obviousness arguments in district court and PTAB’, held in association with McAndrews, Held & Malloy, will take place on November 4 at 5:00pm London time (12pm Eastern/11am Central/9am Pacific).

      In this webinar speakers will discuss:

      •Obviousness: the evolving legal standard and its policy rationale
      •What PTAB/district data tells us (does not tell us) about trends in obviousness holdings
      •Patent holder tactics to combat obviousness during prosecution and after
      •Strategies for challenging and defending a patent with no validity presumption and a broadest reasonable interpretation
      •Best practices for petitioners at the PTAB and defendants in litigation
      •Practical tips for deploying and combating the objective indicia of non-obviousness

      Confirmed speakers:

      •Robert A. Surrette, President, McAndrews, Held & Malloy
      •Mary Elizabeth Mauro, Intellectual Property Counsel, Stryker Corporation
      •Michael Loney, Americas editor, Managing IP (moderator)

      Read more >
    • Patient centricity 101: How to create content that REALLY communicates Patient centricity 101: How to create content that REALLY communicates Andrew Bromley (SDL); Chris McCourt (SDL); Paul Mitchel (Acurian) Recorded: Feb 23 2016 3:00 pm UTC 53 mins
    • According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.

      As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous. As important as what we are saying and where these conversations are taking place may be, it is only part of the conundrum. Developing, maintaining and managing content is a continuous challenge, made all the more taxing not only by strict internal deadlines but the cultural, linguistic and regulatory challenges that go hand in hand with managing global communications.

      Working with our expert partner SDL , we present a live webinar which will deliver insight and guidance on this topic, look in depth at one of the more traditional areas of patient liaison – trial recruitment – and bring you advice from the ‘frontline’ on what works in tackling these content challenges.

      On this latest live webinar, we’ll be discussing:
      •How to develop patient-centric recruitment content that REALLY communicates
      •Best practices of how to handle the linguistic, cultural and regulatory challenges often faced with creating multilingual patient-centric content
      •How simple content management best practices can help you become more patient centric with your content
      •Recent case studies: we’ll be discussing recent successes of global pharmaceutical businesses that have optimised and streamlined recruitment processes with relevant, accurate content development in the right language.

      Read more >
    • The truth about delivering clinical research in the UK? The truth about delivering clinical research in the UK? Dr Matt Cooper, Business Development and Marketing Director Recorded: Mar 2 2016 8:00 am UTC 34 mins
    • •Are you looking to deliver your research within Europe?
      •Do you need multiple, reliable sites and experienced investigators?
      •Do you want to know why you should come to the UK?

      In the past the UK’s reputation for delivering clinical research was questionable. But that has all changed with the Department of Health’s investment in the clinical research network infrastructure in the UK.

      Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical Company, Contract Research Organisation, Biotech, Med Tech or Diagnostic company we can help.

      The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Dr Matt Cooper, Business Development and Marketing Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for running clinical research studies.

      You can discover:
      •How much the UK’s market volume of commercial contract research has grown and how we recruited over 34,000 patients to commercial clinical trials in 2014/15
      •What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
      •The free feasibility service run by the NIHR CRN
      •How to gain access to our experienced clinical experts
      •How we are keeping clinical research in the public eye
      •How the UK is sharpening its competitive edge by achieving more key first global patients

      The NIHR CRN is exhibiting at the BioPharma Asia Convention 2016, visit stand B22 from 22-24 March to find out more about what we do to support clinical research and how we can help you deliver your studies in the UK.

      Read more >
    • The truth about delivering clinical research in the UK The truth about delivering clinical research in the UK Matt Cooper Business Development and Marketing Director Recorded: Jan 27 2016 4:00 pm UTC 39 mins
    • •Are you looking to deliver your research within Europe?
      •Do you need multiple, reliable sites and experienced investigators?
      •Do you want to know why you should come to the UK?

      In the past the UK’s reputation for delivering clinical research was questionable. But that has all changed. Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical company, Contract Research Organisation, Biotech, Med Tech or Diagnostic we can help.

      The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Matt Cooper, Business Development and Marketing Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for clinical research. You can discover:
      •How much the UK’s market volume of commercial contract research (supported by the NIHR CRN) has changed and how we recruited more than 34,000 patients to commercial clinical trials in 2014/15
      •What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
      •The free feasibility service run by the Network
      •How to gain access to clinical experts
      •What percentage of commercial contract studies (supported by the NIHR CRN) are delivered to time and target
      •How we are keeping clinical research in the public eye
      •How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones

      Read more >
    • E2E, VoLTE, VoWiFi Monitoring Solution E2E, VoLTE, VoWiFi Monitoring Solution Nandan Naik Upcoming: May 12 2016 2:00 am UTC 60 mins
    • Operators are increasingly turning to VoLTE and WiFi Calling (VoWiFi) to protect their lucrative voice business against the ever increasing rise of “free” over the top (OTT) applications. The challenges they are facing relate to various deployment phases, including network rollout, beta trials leading to commercial deployments and network optimization with focus on coverage, signaling, audio quality and handovers.

      How have VoLTE and VoWiFi deployment strategies evolved from work process automation challenges faced by operators in the field?

      Register for this webinar to learn how you can optimize quality of service and experience by continuously monitoring, assuring, segmenting and troubleshooting VoLTE and VoWiFi deployments via Smart-device probes.

      Read more >
    • Personalized Medicine - Your Opportunity to Partner with SAP Personalized Medicine - Your Opportunity to Partner with SAP Clemens Suter-Crazzolara, PhD, SAP SE and Puspen Chattopadhyay, MBA, SAP SE Recorded: Apr 7 2016 1:55 pm UTC 51 mins
    • A dramatic health-related revolution is taking place in society – affecting healthcare, life sciences, public sector, higher education, insurance and consumer products.

      Automated diagnosis, the empowerment of the patient, the advance of genomics and the need and capability to analyze massive amounts of big data: all of these drive innovation to improve drug-, therapy-, and medical device-development.

      SAP is uniquely positioned to help advance personalized medicine. Its sophisticated platforms and advanced analytic solutions can help unlock the value of data – from genome to electronic medical record to clinical trial. By facilitating integration, real-time analysis, and reporting of biomedical data, SAP solutions support insights that ultimately lead to better patient outcomes. Learn about exciting new SAP technology and products: SAP Foundation for Health, SAP Medical Research Insights and SAP Health Engagement are in use at customers. These products will enable new and existing SAP partners to join SAP on the personalized medicine journey.

      Read more >
    • Pitfalls in Post-Grant Proceedings Pitfalls in Post-Grant Proceedings Eugene Perez, partner, BSKB; Gerald Murphy, partner, BSKB; Michael Loney, Americas editor, Managing IP Recorded: Apr 16 2015 8:00 pm UTC 62 mins
    • Managing IP’s next webinar, run in cooperation with Birch Stewart Kolasch Birch LLP, will take place on April 16 at 4pm (eastern standard time); 1pm (pacific standard time) and will discuss ‘Pitfalls in Post-Grant Proceedings’.

      With the passage of the America Invents Act in 2011, the number of filings for USPTO post-grant patent trials has dramatically increased. Whether it is an inter partes review, a post-grant review, or a post-grant validity review of qualified business method patents, each PTAB trial has procedural pitfalls with considerable strategic considerations, even before the PTAB makes an institution decision (also known as the First Phase of the trial).

      This webinar will explore the most common mistakes for the third party petitioner and patent owner made during the 1st Phase, with an explanation of key decisions by the PTAB (including those posted on the USPTO microsite) as well as the Federal Circuit. The focus will be on the real party in interest requirement (including privity), joinder and claim construction (interpretation) using the broadest reasonable interpretation standard.

      Speakers include:
      •Michael Loney, Americas editor, Managing IP (moderator)
      •Eugene Perez, partner, Birch Stewart Kolasch Birch LLP
      •Gerald Murphy, partner, Birch Stewart Kolasch Birch LLP

      With post-grant proceedings becoming increasingly popular, having an in-depths understanding of the pitfalls and challenges is essential for sustaining a strong presence in the market place. The live audience will be able to ask questions of the speakers during the webinar, which will be in English and will last one hour.

      Also, don’t forget to mark your calendar for May 12, when we will follow up with a second webinar on ‘Pitfalls in Post Grant Trials’.

      Read more >